Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, ...

The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing ...

Roche has already signed several high-ticket deals this year, including the $3.5 billion acquisition of 89bio and Genentech’s ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...

In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how small ...

As mRNA continues to enter and be adopted by the global healthcare community, the need to quickly validate and scale these ...

The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in ...

Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone.

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.